triiodothyronine has been researched along with Multiple Sclerosis in 12 studies
Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.
3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.
Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Liothyronine was tolerated well without treatment-related severe/serious adverse events or evidence of disease activation/clinical deterioration." | 3.30 | A Phase 1b, Open-Label Study to Evaluate the Safety and Tolerability of the Putative Remyelinating Agent, Liothyronine, in Individuals with MS. ( Bhargava, P; Calabresi, PA; Cassard, SD; Cooper, DS; Fiol, J; Fitzgerald, KC; Mammen, JSR; Mowry, EM; Newsome, SD; Shoemaker, T; Snoops, S; Tian, F, 2023) |
| " The objectives of this single-center, phase I, placebo-controlled, clinical trial were to determine the safety, tolerability, and optimal dosing of L-T3 in people with MS in preparation for a phase 2 remyelination clinical trial." | 2.94 | Phase I randomized trial of liothyronine for remyelination in multiple sclerosis: A dose-ranging study with assessment of reliability of visual outcomes. ( Altowaijri, G; Bourdette, D; Cameron, M; Hildebrand, A; Oken, B; Samuels, M; Wooliscroft, L, 2020) |
| "Nevertheless, very few cases of Graves' disease, occurred in such condition, have been reported in literature." | 1.31 | Long-term treatment with interferon-beta therapy for multiple sclerosis and occurrence of Graves' disease. ( Amato, G; Biondi, B; Carella, C; Del Buono, AD; di Cristofaro, M; Di Iorio, G; Manganella, G; Mazziotti, G; Montella, P; Rotondi, M, 2000) |
| "Interferon beta (IFNB) treatment for multiple sclerosis (MS) has been associated with thyroid disorders (TD), in particular in patients with subclinical TD or anti-thyroid (AT) autoantibodies (autoAb) before starting treatment." | 1.31 | Thyroid function and anti-thyroid antibodies in MS patients screened for interferon treatment. A multicenter study. ( Barbero, P; Bergamasco, B; Brossa, PC; Durelli, L; Faggiano, F; Ghigo, E; Isoardo, GL; Maccario, M; Oggero, A; Verdun, E, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 3 (25.00) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Newsome, SD | 1 |
| Tian, F | 1 |
| Shoemaker, T | 1 |
| Fitzgerald, KC | 1 |
| Cassard, SD | 1 |
| Fiol, J | 1 |
| Snoops, S | 1 |
| Cooper, DS | 1 |
| Mammen, JSR | 1 |
| Bhargava, P | 1 |
| Mowry, EM | 1 |
| Calabresi, PA | 1 |
| Wooliscroft, L | 1 |
| Altowaijri, G | 1 |
| Hildebrand, A | 1 |
| Samuels, M | 1 |
| Oken, B | 1 |
| Bourdette, D | 1 |
| Cameron, M | 1 |
| Marot, D | 1 |
| Maquart, FX | 1 |
| Delemer, B | 1 |
| Decoudier, B | 1 |
| D'Intino, G | 1 |
| Lorenzini, L | 1 |
| Fernandez, M | 1 |
| Taglioni, A | 1 |
| Perretta, G | 1 |
| Del Vecchio, G | 1 |
| Villoslada, P | 1 |
| Giardino, L | 1 |
| Calzà, L | 1 |
| Zhang, B | 1 |
| Jiang, Y | 1 |
| Yang, Y | 1 |
| Peng, F | 1 |
| Hu, X | 1 |
| Kiessling, WR | 1 |
| Pflughaupt, KW | 1 |
| Haubitz, I | 1 |
| Mertens, HG | 1 |
| Demerens, C | 1 |
| Stankoff, B | 1 |
| Zalc, B | 1 |
| Lubetzki, C | 1 |
| Rotondi, M | 2 |
| Oliviero, A | 1 |
| Profice, P | 1 |
| Mone, CM | 1 |
| Biondi, B | 2 |
| Del Buono, A | 1 |
| Mazziotti, G | 2 |
| Sinisi, AM | 1 |
| Bellastella, A | 1 |
| Carella, C | 2 |
| Manganella, G | 1 |
| Del Buono, AD | 1 |
| Montella, P | 1 |
| di Cristofaro, M | 1 |
| Di Iorio, G | 1 |
| Amato, G | 1 |
| Durelli, L | 2 |
| Ferrero, B | 1 |
| Oggero, A | 2 |
| Verdun, E | 2 |
| Ghezzi, A | 1 |
| Montanari, E | 1 |
| Zaffaroni, M | 1 |
| Isoardo, GL | 1 |
| Barbero, P | 1 |
| Bergamasco, B | 1 |
| Brossa, PC | 1 |
| Ghigo, E | 1 |
| Maccario, M | 1 |
| Faggiano, F | 1 |
| Golovkin, VI | 1 |
| Korovin, KF | 1 |
| Iampol'skaia, LI | 1 |
| Dobrov, SA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study[NCT02760056] | Phase 1 | 15 participants (Actual) | Interventional | 2016-06-06 | Completed | ||
| Characteristic Study on Chinese Patients With Multiple Sclerosis[NCT00818103] | 600 participants (Anticipated) | Interventional | 2006-01-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
MTD per protocol (dose level one category below dose at which study was stopped due to intolerance or meeting criteria for cessation) (NCT02760056)
Timeframe: 1 week
| Intervention | mcg daily with BID dosing (Number) |
|---|---|
| Liothyronine (Cytomel) | 75 |
P100 latency will be compared before and after treatment with L-T3 in subjects receiving the active treatment to assess reliability of the test for future assessment of treatment effect. (NCT02760056)
Timeframe: 1 week
| Intervention | Intraclass Coefficient (ICC) (Number) | ||
|---|---|---|---|
| ICC - Right Eye | ICC - Left Eye | ICC- Mixed Model | |
| All Participants | 0.824 | 0.845 | 0.924 |
| Liothyronine (Cytomel) | 0.852 | 0.746 | 0.889 |
| Placebo | 0.679 | 0.966 | 0.963 |
3 trials available for triiodothyronine and Multiple Sclerosis
| Article | Year |
|---|---|
A Phase 1b, Open-Label Study to Evaluate the Safety and Tolerability of the Putative Remyelinating Agent, Liothyronine, in Individuals with MS.
Topics: Central Nervous System; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Oligodendroglia; Prot | 2023 |
Phase I randomized trial of liothyronine for remyelination in multiple sclerosis: A dose-ranging study with assessment of reliability of visual outcomes.
Topics: Adult; Evoked Potentials, Visual; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Outcome Ass | 2020 |
Thyroid function and autoimmunity during interferon beta-1b treatment: a multicenter prospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Autoantibodies; Female; Humans; Interferon beta-1a; Inte | 2001 |
9 other studies available for triiodothyronine and Multiple Sclerosis
| Article | Year |
|---|---|
Consistent, but Totally Misleading, Thyroid Function Test Results.
Topics: Aged; Antibody Affinity; Biotin; False Positive Reactions; Humans; Hyperthyroidism; Immunoassay; Mal | 2017 |
Triiodothyronine administration ameliorates the demyelination/remyelination ratio in a non-human primate model of multiple sclerosis by correcting tissue hypothyroidism.
Topics: Animals; Biomarkers; Callithrix; Demyelinating Diseases; Disease Models, Animal; Encephalomyelitis, | 2011 |
Correlation between serum thyroxine and complements in patients with multiple sclerosis and neuromyelitis optica.
Topics: Adolescent; Adult; Complement System Proteins; Female; Humans; Male; Middle Aged; Multiple Sclerosis | 2008 |
Thyroid function in multiple sclerosis.
Topics: Adolescent; Adult; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Thyroid Gland; Thyrotropin | 1980 |
Eliprodil stimulates CNS myelination: new prospects for multiple sclerosis?
Topics: Animals; Axons; Central Nervous System; Coculture Techniques; Drug Evaluation, Preclinical; Forecast | 1999 |
Occurrence of thyroid autoimmunity and dysfunction throughout a nine-month follow-up in patients undergoing interferon-beta therapy for multiple sclerosis.
Topics: Adult; Autoantibodies; Autoimmune Diseases; Autoimmunity; Female; Humans; Interferon-beta; Iodide Pe | 1998 |
Long-term treatment with interferon-beta therapy for multiple sclerosis and occurrence of Graves' disease.
Topics: Adult; Autoantibodies; Female; Graves Disease; Humans; Interferon beta-1a; Interferon beta-1b; Inter | 2000 |
Thyroid function and anti-thyroid antibodies in MS patients screened for interferon treatment. A multicenter study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Autoantibodies; Causality; Female; Humans; Interferons; | 2001 |
[Neuroendocrine aspects of the pathogenesis and treatment of disseminated sclerosis and lateral amyotrophic sclerosis].
Topics: Adult; Amyotrophic Lateral Sclerosis; Arginine Vasopressin; Diagnosis, Differential; Drug Therapy, C | 1990 |